Plecanatide: First Global Approval

@article{AlSalama2017PlecanatideFG,
  title={Plecanatide: First Global Approval},
  author={Zaina T. Al-Salama and Yahiya Y. Syed},
  journal={Drugs},
  year={2017},
  volume={77},
  pages={593-598}
}
Plecanatide (TrulanceTM) is an oral guanylate cyclase-C agonist that is being developed by Synergy Pharmaceuticals for the treatment of gastrointestinal disorders, such as chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). It is a synthetic analogue of human uroguanylin, a 16 amino acid peptide that regulates ion and fluid transport in the gastrointestinal tract. In January 2017, plecanatide received its first global approval in the USA for the… 
Plecanatide for the treatment of chronic idiopathic constipation in adult patients
TLDR
Experimental studies showed that plecanatide was significantly better than placebo in reducing CIC severity, straining, stool consistency, bowel movements and quality of life and this new agent with a different way of action can be proposed in patients refractory to common therapy.
An update on prucalopride in the treatment of chronic constipation
TLDR
One such agent is prucalopride, which has now been approved for the management of chronic idiopathic constipation in several countries, but not in the United States, and has enjoyed a favorable safety profile and there have been no signals to suggest arrythmogenicity.
Liquid-Phase Total Synthesis of Plecanatide Aided by Diphenylphosphinyloxyl Diphenyl Ketone (DDK) Derivatives.
TLDR
Diphenylphosphinyloxyl diphenyl ketone (DDK) derivatives are developed as greener supports with unique precipitation-inducing properties to aid the liquid-phase total synthesis of plecanatide without the use of chromatography.
PLECANATIDE: “path maker for exertion to bowel relaxation”
TLDR
Constipation is the irregular and difficult stool passage associated with straining or sensation of incomplete evacuation and plecanatide being the latest which was approved by food and drug administration in January 2017 for CIC, followed by approval for IBS-C in January 2018.
Guanylin, Uroguanylin and Guanylate Cyclase-C Are Expressed in the Gastrointestinal Tract of Horses
TLDR
The gene expression of guanylin, uroguanylin and GC-C receptors in different horse’s gastrointestinal tracts is investigated for the first time and a common pattern of expression throughout the gastrointestinal lumen for all three investigated transcripts was found.
Luminally Acting Agents for Constipation Treatment: A Review Based on Literatures and Patents
TLDR
The present review covers the discovery of luminally acting agents for constipation treatment described in both patents (2011–present) and scientific literatures.
The Guanylate Cyclase C—cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia
TLDR
Findings suggest an intriguing hypothesis that colorectal cancer arises in a microenvironment of functional GUCY2C inactivation, which can be repaired by oral ligand replacement, and represents a novel therapeutic target for preventing coloreCTal cancer.
Recent advances in understanding and managing chronic constipation
TLDR
Advances in understanding of colonic molecular physiology have led to the development of new therapeutic agents (such as secretagogues, pro-kinetics, inhibitors of bile acid transporters and ion exchangers), however, because clinical trials compare these newer agents with placebo, their efficacy relative to traditional laxatives is unknown.
Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies
  • J. Palma, H. Kaufmann
  • Medicine
    Movement disorders : official journal of the Movement Disorder Society
  • 2018
TLDR
The treatment of autonomic dysfunction in patients with Parkinson disease and other synucleinopathies is reviewed, the nonpharmacological and current pharmacological therapeutic strategies including recently approved drugs are summarized, and practical advice and management algorithms for clinicians are provided.
2017 FDA Peptide Harvest
TLDR
The six peptides included in this list are analyzed in terms of chemical structure, synthetic strategy used for their production, source, therapeutic use, and mode of action.
...
1
2
...

References

SHOWING 1-10 OF 22 REFERENCES
Plecanatide, an Oral Guanylate Cyclase C Agonist Acting Locally in the Gastrointestinal Tract, Is Safe and Well-Tolerated in Single Doses
TLDR
Plecanatide, an oral GC-C agonist, acting locally within the GI tract without measurable systemic exposure, was safe and well-tolerated in single doses up to 48.6 mg.
A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation
TLDR
Results suggest that plecanatide will be a useful treatment option in the management of CIC and significantly improved constipation and its related symptoms with a low rate of adverse events.
Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis.
TLDR
This is the first-ever study reporting the therapeutic utility of GC-C agonists as a new class of orally delivered and mucosally active drug candidates for the treatment of inflammatory bowel diseases.
Trulance (plecanatide) tablets: US prescribing information. 2017
  • http://content.stockpr.com/synergypharma/files/ pages/synergypharma/db/147/description/03?Plecanatide?label_ clean_2017-01-19.pdf. Accessed
  • 2017
FDA approves Trulance for chronic idiopathic constipation
  • [media release]
  • 2017
FDA approves Trulance for chronic idiopathic constipation [media release
  • 2017
Effect of plecanatide on patient assessments in chronic idiopathic constipation ( CIC ) : results from two phase III studies [ abstract no . Sa 1443 ]
  • 2016
Effect of plecanatide on stool consistency in the treatment of chronic idiopathic constipation ( CIC ) : results from two phase III studies [ abstract no . Sa 1444 ]
  • Gastroenterology
  • 2016
...
1
2
3
...